Indications for the peptide enhanced bone graft now include single-level anterior cervical discectomy fusion with an allograft bone ring. It can also be used in conjunction with a PEEK titanium alloy or fusion device that has been cleared by the FDA for cervical spine use.
The i-Factor bone graft has been used in the U.S. since 2015, Cerapedic CEO Valeska Schroeder said in the release. It is reportedly the only product of its kind that used a P-15 osteogenic cell binding peptide, and studies show it is as safe as a local autograft in single-level ACDF.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
